VRPX News and Press, Virpax Pharmaceuticals Inc. From 02/27/24

VRPX - Virpax Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq's Minimum Bid Price

Virpax ® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barrier indica...

VRPX - Virpax Pharmaceuticals Announces Preliminary Results of ProbudurTM Pilot Study with the U.S. Army Institute of Surgical Research

Virpax ® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barrier indi...

VRPX - Virpax Pharmaceuticals shareholders okay reverse stock split

2023-12-29 15:49:49 ET More on Virpax Pharmaceuticals Virpax Pharmaceuticals gets non-compliance notice from Nasdaq Seeking Alpha’s Quant Rating on Virpax Pharmaceuticals Historical earnings data for Virpax Pharmaceuticals Financial information for Vir...

VRPX - Virpax Pharmaceuticals Announces Results of Special Shareholders Meeting

Virpax ® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barriers, to...

VRPX - Virpax Pharmaceuticals gets non-compliance notice from Nasdaq

2023-11-17 08:41:25 ET More on Virpax Pharmaceuticals Virpax slips as court rules in favor of Scilex and Sorrento Seeking Alpha’s Quant Rating on Virpax Pharmaceuticals Historical earnings data for Virpax Pharmaceuticals Financial information for Virpa...

VRPX - Virpax Pharmaceuticals CEO and Chairman resigns on ongoing litigation

2023-11-17 07:38:01 ET More on Virpax Pharmaceuticals Seeking Alpha’s Quant Rating on Virpax Pharmaceuticals Historical earnings data for Virpax Pharmaceuticals Financial information for Virpax Pharmaceuticals For further details see: Virpax Pharma...

VRPX - Virpax Pharmaceuticals Announces Notification from Nasdaq Related to Delayed Form 10-Q Filing

Virpax ® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barriers, to...

VRPX - Virpax Pharmaceuticals Announces Leadership Transition

Virpax ® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barrier indi...

VRPX - Virpax Pharmaceuticals GAAP EPS of -$0.51

2023-11-15 18:02:42 ET Virpax Pharmaceuticals press release ( NASDAQ: VRPX ): Q3 GAAP EPS of -$0.51. As of September 30, 2023, cash and cash equivalents were $12.2 million. For further details see: Virpax Pharmaceuticals GAAP EPS of -$0.51

VRPX - Virpax Pharmaceuticals Reports 2023 Third Quarter Results and Recent Developments

Virpax ® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX) , a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and viral barrier indica...

Company Name:	Virpax Pharmaceuticals Inc.
Stock Symbol:	VRPX
Market:	NASDAQ